In recent years phosphodiesterase V acts as an attractive target for cardiovascular drug design and QSAR techniques are helpful for the optimization of structural requirements for designing novel compounds.
In the present work a cardiovascular simulator designed both for clinical and training use is presented.
As its name implies, this chapter will provide an overview of cardiovascular stent designs, with particular focus given to drug-eluting stents.
However, little is known about the anti-coagulation, anti-inflammatory, anti-atherosclerosis and anti-shedding property of the attached endothelial cells (ECs) and the relationship with their bio-environment and material-environment, which are both important evaluations to the cardiovascular biomaterials designed for tissue engineering applications and in vivo implantation.
ACCORD is a randomized trial of cardiovascular outcomes, designed to compare an intensive therapeutic strategy targeting normal A1C levels (i.e., <6.0%), with a standard strategy targeting A1C levels from 7.0 to 7.9% in a population with long-standing type 2 diabetes and a history of cardiovascular disease (CVD) or significant cardiovascular risk factors.
Example applications include aircraft design, cardiovascular system modeling, electronic structure computation, and tomographic imaging.
Future studies need to focus on unraveling the mechanisms by which uremia leads to increased cardiovascular events to design optimal therapies targeted toward these mechanisms and improve cardiovascular outcomes.
We extracted data on: study design, cardiovascular risk factor(s) and their measurement, diagnosis of SMI, study setting, sampling method, nature of comparison group and data on key risk factors.
"Aerobic or cardiovascular training is designed to develop a healthier heart and circulatory system," says Howard Knuttgen, research associate in physical medicine and rehabilitation at Harvard-affiliated Spaulding Rehabilitation Hospastl and a presidentident of the American College of Sports Medicine.
